RT Journal Article
SR Electronic
T1 Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 75S
OP 80S
DO 10.2967/jnumed.115.157933
VO 57
IS Supplement 1
A1 Amy M. Fowler
A1 Amy S. Clark
A1 John A. Katzenellenbogen
A1 Hannah M. Linden
A1 Farrokh Dehdashti
YR 2016
UL http://jnm.snmjournals.org/content/57/Supplement_1/75S.abstract
AB Estrogen receptor alpha (ERα) and progesterone receptor (PR) are important steroid hormone receptor biomarkers used to determine prognosis and to predict benefit from endocrine therapies for breast cancer patients. Receptor expression is routinely measured in biopsy specimens using immunohistochemistry, although such testing can be challenging, particularly in the setting of metastatic disease. ERα and PR can be quantitatively assayed noninvasively with PET. This approach provides the opportunity to assess receptor expression and function in real time, within the entire tumor, and across distant sites of metastatic disease. This article reviews the current evidence of ERα and PR PET imaging as predictive and early-response biomarkers for endocrine therapy.